8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
May 5, 2026·SEC
Material company update
Apr 30, 2026·SEC
Phibro Animal Health Corporation(PAHC)Earnings, Financials & Key Ratios
PAHC•NASDAQ
$58.64
$2.38B mkt cap·49.3× P/E·Price updated May 6, 2026
SectorHealthcareIndustrySpecialty & Generic PharmaSub-IndustryAnimal health pharmaceuticals and vaccines
AboutPhibro Animal Health Corporation develops, manufactures, and supplies a range of animal health and mineral nutrition products for livestock primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also comprise antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent bacterial diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic intestinal worms; and anti-bloat treatment products for cattle to control bloat in animals grazing on legume or wheat-pasture. In addition, the company offers nutritional specialty products, which enhance nutrition to help improve health and performance; and vaccines to prevent diseases primarily for the poultry and swine markets. Further, it manufactures and markets formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron, and other compounds; and various specialty ingredients for use in the personal care, industrial chemical, and chemical catalyst industries. The company sells its animal health and mineral nutrition products through local sales offices to integrated poultry, swine, and cattle integrators, as well as through commercial animal feed manufacturers, wholesalers, and distributors. It operates in the United States, Latin America, Canada, Europe, the Middle East, Africa, and the Asia Pacific. The company was formerly known as Philipp Brothers Chemicals, Inc. and changed its name to Phibro Animal Health Corporation in July 2003. Phibro Animal Health Corporation was incorporated in 2014 and is headquartered in Teaneck, New Jersey.Show more
- Revenue$1.3B+27.4%
- EBITDA$156M+74.4%
- Net Income$48M+1897.7%
- EPS (Diluted)1.19+1883.3%
- Gross Margin30.85%+0.3%
- EBITDA Margin12.04%+36.9%
- Operating Margin8.52%+62.7%
- Net Margin3.72%+1468.4%
- ROE17.8%+1886.1%
- ROIC9.8%+79.3%
- Debt/Equity2.67+30.2%
- Interest Coverage3.04+103.4%
PAHC Key Insights
Phibro Animal Health Corporation (PAHC) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 82 (top 18%)
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 10.1%
- ✓Trading near 52-week high
✗Weaknesses
- ✗High debt to equity ratio of 2.7x
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PAHC Price & Volume
Phibro Animal Health Corporation (PAHC) stock price & volume — 10-year historical chart
Loading chart...
PAHC Growth Metrics
Phibro Animal Health Corporation (PAHC) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years5.64%
5 Years10.12%
3 Years11.22%
TTM32.39%
Profit CAGR
10 Years-2.2%
5 Years7.54%
3 Years-0.62%
TTM376.73%
EPS CAGR
10 Years-2.35%
5 Years7.47%
3 Years-0.55%
TTM370.12%
Return on Capital
10 Years13.35%
5 Years10.14%
3 Years9.37%
Last Year11.97%
PAHC Recent Earnings
Phibro Animal Health Corporation (PAHC) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 6/12 qtrs (50%)
Q1 2026Latest
Feb 4, 2026EPS
$0.87
Est $0.69
+26.1%
Revenue
$374M
Est $356M
+5.1%
Q4 2025
Nov 5, 2025EPS
$0.73
Est $0.59
+23.7%
Revenue
$364M
Est $345M
+5.3%
Q3 2025
Aug 27, 2025EPS
$0.57
Est $0.52
+9.6%
Revenue
$379M
Est $362M
+4.5%
Q2 2025
May 7, 2025EPS
$0.63
Est $0.52
+21.2%
Revenue
$348M
Est $362M
-4.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 4, 2026 | $0.87vs $0.69+26.1% | $374Mvs $356M+5.1% |
| Q4 2025 | Nov 5, 2025 | $0.73vs $0.59+23.7% | $364Mvs $345M+5.3% |
| Q3 2025 | Aug 27, 2025 | $0.57vs $0.52+9.6% | $379Mvs $362M+4.5% |
| Q2 2025 | May 7, 2025 | $0.63vs $0.52+21.2% | $348Mvs $362M-4.0% |
Based on last 12 quarters of dataView full earnings history →
PAHC Peer Comparison
Phibro Animal Health Corporation (PAHC) competitors in Animal health pharmaceuticals and vaccines — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ELAN | 13.06B | 26.16 | -55.66 | 6.22% | -4.95% | -3.64% | 0.61 | |
 ZTS | 46.95B | 111.22 | 18.48 | 2.28% | 28.23% | 58.23% | 2.85 | |
 NEOG | 2B | 9.18 | -1.83 | -3.2% | -68.47% | -28.64% | 0.44 | |
 IDXX | 46.12B | 579.23 | 44.28 | 10.42% | 24.63% | 70.87% | 0.67 | |
 TSN | 24.24B | 68.09 | 50.07 | 2.12% | 0.81% | 2.48% | 0.48 | |
 HRL | 11.39B | 20.70 | 23.79 | 1.55% | 4.03% | 4.3% | 0.36 | |
 PPC | 7.45B | 31.30 | 6.89 | 3.46% | 4.78% | 24.09% | 0.91 | |
 CAG | 6.73B | 14.07 | 5.84 | 0.12% | 0.16% | 0.93 |
Compare PAHC vs Peers
Phibro Animal Health Corporation (PAHC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PAHC Income Statement
Phibro Animal Health Corporation (PAHC) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 764.3M | 820M | 828M | 800.35M | 833.35M | 942.26M | 977.89M | 1.02B | 1.3B | 1.46B |
| Revenue Growth % | 1.7% | 7.29% | 0.98% | -3.34% | 4.12% | 13.07% | 3.78% | 4.07% | 27.37% | 32.39% |
| Cost of Goods Sold | 516M | 553.1M | 563.4M | 543.47M | 561.97M | 656.86M | 679.65M | 704.59M | 896.27M | 997.31M |
| COGS % of Revenue | 67.51% | 67.45% | 68.04% | 67.9% | 67.44% | 69.71% | 69.5% | 69.23% | 69.15% | - |
| Gross Profit | 248.3M▲ 0% | 266.9M▲ 7.5% | 264.6M▼ 0.9% | 256.88M▼ 2.9% | 271.38M▲ 5.6% | 285.4M▲ 5.2% | 298.24M▲ 4.5% | 313.09M▲ 5.0% | 399.94M▲ 27.7% | 467.02M▲ 0% |
| Gross Margin % | 32.49% | 32.55% | 31.96% | 32.1% | 32.56% | 30.29% | 30.5% | 30.77% | 30.85% | 31.89% |
| Gross Profit Growth % | 3.89% | 7.49% | -0.86% | -2.92% | 5.64% | 5.17% | 4.5% | 4.98% | 27.74% | - |
| Operating Expenses | 150.3M | 168M | 181.4M | 187.69M | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M | 296.7M |
| OpEx % of Revenue | 19.67% | 20.49% | 21.91% | 23.45% | 23.58% | 21.91% | 23.15% | 25.53% | 22.33% | - |
| Selling, General & Admin | 150.3M | 168M | 181.4M | 187.69M | 196.51M | 206.41M | 226.39M | 259.78M | 289.48M | 296.7M |
| SG&A % of Revenue | 19.67% | 20.49% | 21.91% | 23.45% | 23.58% | 21.91% | 23.15% | 25.53% | 22.33% | - |
| Research & Development | 9.44M | 10M | 12.08M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| R&D % of Revenue | 1.24% | 1.22% | 1.46% | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | 97.9M▲ 0% | 98.9M▲ 1.0% | 73.3M▼ 25.9% | 69.19M▼ 5.6% | 74.87M▲ 8.2% | 78.99M▲ 5.5% | 71.85M▼ 9.0% | 53.31M▼ 25.8% | 110.47M▲ 107.2% | 169.54M▲ 0% |
| Operating Margin % | 12.81% | 12.06% | 8.85% | 8.65% | 8.98% | 8.38% | 7.35% | 5.24% | 8.52% | 11.58% |
| Operating Income Growth % | 14.24% | 1.02% | -25.88% | -5.6% | 8.2% | 5.5% | -9.04% | -25.79% | 107.19% | - |
| EBITDA | 123.9M | 125.84M | 100.86M | 101.53M | 106.75M | 111.69M | 105.86M | 89.49M | 156.07M | 220.29M |
| EBITDA Margin % | 16.21% | 15.35% | 12.18% | 12.69% | 12.81% | 11.85% | 10.83% | 8.79% | 12.04% | 15.04% |
| EBITDA Growth % | 13.51% | 1.57% | -19.85% | 0.66% | 5.13% | 4.63% | -5.22% | -15.46% | 74.39% | 82.74% |
| D&A (Non-Cash Add-back) | 26M | 26.94M | 27.56M | 32.34M | 31.88M | 32.7M | 34.01M | 36.18M | 45.6M | 50.75M |
| EBIT | 97.42M | 100.79M | 85.18M | 69.24M | 78.33M | 84.43M | 72.02M | 32.89M | 101.24M | 175.23M |
| Net Interest Income | -14.91M | -11.91M | -11.78M | -12.55M | -9.56M | -11.29M | -14.59M | -17.5M | -30.63M | -46.17M |
| Interest Income | 1.97M | 1.69M | 1.9M | 1.76M | 838K | 816K | 3.35M | 4.47M | 2.62M | 1.93M |
| Interest Expense | 16.87M | 13.6M | 13.68M | 14.3M | 10.4M | 12.1M | 17.95M | 21.97M | 33.25M | 48.09M |
| Other Income/Expense | -17.39M | -10.86M | -11.72M | -13.68M | -8.4M | -6.66M | -17.78M | -42.4M | -42.47M | -43.31M |
| Pretax Income | 80.5M▲ 0% | 88.1M▲ 9.4% | 71.5M▼ 18.8% | 55.51M▼ 22.4% | 66.47M▲ 19.7% | 72.33M▲ 8.8% | 54.07M▼ 25.2% | 10.92M▼ 79.8% | 67.99M▲ 522.9% | 126.23M▲ 0% |
| Pretax Margin % | 10.53% | 10.74% | 8.64% | 6.94% | 7.98% | 7.68% | 5.53% | 1.07% | 5.25% | 8.62% |
| Income Tax | 15.9M | 23.2M | 16.8M | 21.96M | 12.08M | 23.15M | 21.46M | 8.5M | 19.73M | 34.14M |
| Effective Tax Rate % | 19.75% | 26.33% | 23.5% | 39.56% | 18.18% | 32.01% | 39.7% | 77.87% | 29.02% | 27.04% |
| Net Income | 64.6M▲ 0% | 64.9M▲ 0.5% | 54.7M▼ 15.7% | 33.55M▼ 38.7% | 54.38M▲ 62.1% | 49.17M▼ 9.6% | 32.61M▼ 33.7% | 2.42M▼ 92.6% | 48.26M▲ 1897.7% | 92.09M▲ 0% |
| Net Margin % | 8.45% | 7.91% | 6.61% | 4.19% | 6.53% | 5.22% | 3.33% | 0.24% | 3.72% | 6.29% |
| Net Income Growth % | -21.89% | 0.46% | -15.72% | -38.66% | 62.09% | -9.58% | -33.69% | -92.59% | 1897.68% | 376.73% |
| Net Income (Continuing) | 64.61M | 64.88M | 54.71M | 33.55M | 54.38M | 49.17M | 32.61M | 2.42M | 48.26M | 92.09M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.61▲ 0% | 1.61▲ 0.0% | 1.35▼ 16.1% | 0.83▼ 38.5% | 1.34▲ 61.4% | 1.21▼ 9.7% | 0.81▼ 33.1% | 0.06▼ 92.6% | 1.19▲ 1883.3% | 2.25▲ 0% |
| EPS Growth % | -22.22% | 0% | -16.15% | -38.52% | 61.45% | -9.7% | -33.06% | -92.59% | 1883.33% | 370.12% |
| EPS (Basic) | 1.63 | 1.61 | 1.35 | 0.83 | 1.34 | 1.21 | 0.81 | 0.06 | 1.19 | - |
| Diluted Shares Outstanding | 40M | 40.4M | 40.52M | 40.5M | 40.5M | 40.5M | 40.5M | 40.52M | 40.7M | 40.96M |
| Basic Shares Outstanding | 39.5M | 40.2M | 40.41M | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.5M | 40.53M |
| Dividend Payout Ratio | 24.5% | 24.77% | 33.99% | 57.87% | 35.73% | 39.54% | 59.63% | 804.72% | 40.3% | - |
PAHC Balance Sheet
Phibro Animal Health Corporation (PAHC) balance sheet — assets, liabilities & shareholders' equity
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 363.67M | 415.46M | 466.16M | 451.84M | 498.91M | 566.23M | 585.72M | 601M | 810.61M | 862.18M |
| Cash & Short-Term Investments | 56.08M | 79.17M | 81.57M | 91.34M | 93.21M | 91.25M | 81.28M | 114.61M | 77.04M | 74.51M |
| Cash Only | 56.08M | 29.17M | 57.57M | 36.34M | 50.21M | 74.25M | 41.28M | 70.61M | 68.04M | 55.49M |
| Short-Term Investments | 0 | 50M | 24M | 55M | 43M | 17M | 40M | 44M | 9M | 19.02M |
| Accounts Receivable | 125.85M | 135.74M | 159.02M | 126.52M | 146.85M | 166.54M | 163.48M | 169.45M | 227.98M | 215.87M |
| Days Sales Outstanding | 60.1 | 60.42 | 70.1 | 57.7 | 64.32 | 64.51 | 61.02 | 60.78 | 64.2 | 53.55 |
| Inventory | 161.23M | 178.17M | 198.32M | 196.66M | 216.31M | 259.16M | 277.57M | 265.91M | 444.43M | 517.35M |
| Days Inventory Outstanding | 114.05 | 117.58 | 128.48 | 132.08 | 140.49 | 144.01 | 149.07 | 137.75 | 180.99 | 172.19 |
| Other Current Assets | 20.5M | 22.38M | 27.25M | 37.31M | 42.53M | 49.29M | 63.39M | 51.02M | 61.16M | 54.46M |
| Total Non-Current Assets | 259.73M | 256.22M | 260.51M | 332.26M | 342.42M | 365.47M | 385.67M | 381.19M | 550.29M | 543.37M |
| Property, Plant & Equipment | 127.35M | 130.11M | 140.24M | 170.98M | 187.67M | 203.17M | 231.33M | 240.9M | 396.03M | 355.38M |
| Fixed Asset Turnover | 6.00x | 6.30x | 5.90x | 4.68x | 4.44x | 4.64x | 4.23x | 4.22x | 3.27x | 3.84x |
| Goodwill | 23.98M | 27.35M | 27.35M | 52.68M | 52.68M | 53.23M | 53.27M | 54.56M | 59.65M | 59.81M |
| Intangible Assets | 54.6M | 51.98M | 47.48M | 71M | 62.28M | 63.86M | 54.99M | 45.03M | 36.47M | 33.07M |
| Long-Term Investments | 9.33M | 9.18M | 9.63M | 10.02M | 10.11M | 10.35M | 11.09M | 11.49M | 11.69M | 49.48M |
| Other Non-Current Assets | 21.2M | 22.18M | 19.05M | 16.16M | 19.82M | 29.02M | 26.28M | 9.83M | 20.91M | 149.22M |
| Total Assets | 623.4M▲ 0% | 671.68M▲ 7.7% | 726.67M▲ 8.2% | 784.1M▲ 7.9% | 841.33M▲ 7.3% | 931.7M▲ 10.7% | 971.4M▲ 4.3% | 982.18M▲ 1.1% | 1.36B▲ 38.6% | 1.41B▲ 0% |
| Asset Turnover | 1.23x | 1.22x | 1.14x | 1.02x | 0.99x | 1.01x | 1.01x | 1.04x | 0.95x | 1.07x |
| Asset Growth % | 2.13% | 7.75% | 8.19% | 7.9% | 7.3% | 10.74% | 4.26% | 1.11% | 38.56% | 125.83% |
| Total Current Liabilities | 115.8M | 143.22M | 154.23M | 157.24M | 164.12M | 190.83M | 176M | 204.15M | 293.47M | 282.37M |
| Accounts Payable | 56.89M | 59.5M | 73.19M | 66.09M | 68.36M | 95.6M | 73.85M | 85.57M | 138.2M | 133.3M |
| Days Payables Outstanding | 40.24 | 39.26 | 47.42 | 44.39 | 44.4 | 53.12 | 39.66 | 44.33 | 56.28 | 48.83 |
| Short-Term Debt | 6.25M | 12.58M | 12.54M | 18.75M | 9.38M | 15M | 22.3M | 29.8M | 16.25M | 20.64M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 37.84M | 54.67M | 43.95M | 47M | 56.21M | 53.18M | 48.22M | 55.15M | 83M | 108.81M |
| Current Ratio | 3.14x | 2.90x | 3.02x | 2.87x | 3.04x | 2.97x | 3.33x | 2.94x | 2.76x | 2.76x |
| Quick Ratio | 1.75x | 1.66x | 1.74x | 1.62x | 1.72x | 1.61x | 1.75x | 1.64x | 1.25x | 1.25x |
| Cash Conversion Cycle | 133.91 | 138.74 | 151.17 | 145.39 | 160.41 | 155.4 | 170.42 | 154.2 | 188.9 | 176.9 |
| Total Non-Current Liabilities | 356.44M | 343.5M | 356.43M | 438.66M | 438.68M | 478.43M | 512.89M | 521.39M | 781.75M | 790.82M |
| Long-Term Debt | 306.89M | 299.8M | 313.63M | 368.26M | 382.71M | 417.93M | 452.54M | 458.29M | 702.43M | 710.6M |
| Capital Lease Obligations | 0 | 0 | 0 | 17.28M | 28M | 31.51M | 29.08M | 29.91M | 33.74M | 133.45M |
| Deferred Tax Liabilities | 8.95M | 9.73M | 8.98M | 11.68M | 6.65M | 9.26M | 12.15M | 14.22M | 19.47M | 78.98M |
| Other Non-Current Liabilities | 40.61M | 33.97M | 33.82M | 41.45M | 21.32M | 19.73M | 19.12M | 18.97M | 26.1M | 99.92M |
| Total Liabilities | 472.24M | 486.73M | 510.66M | 595.9M | 602.8M | 669.26M | 688.89M | 725.54M | 1.08B | 1.07B |
| Total Debt | 313.14M | 312.38M | 326.18M | 410.72M | 426.71M | 470.48M | 509.97M | 525.46M | 761.55M | 773.17M |
| Net Debt | 257.06M | 283.21M | 268.6M | 374.38M | 376.49M | 396.24M | 468.69M | 454.85M | 693.51M | 717.68M |
| Debt / Equity | 2.07x | 1.69x | 1.51x | 2.18x | 1.79x | 1.79x | 1.81x | 2.05x | 2.67x | 2.67x |
| Debt / EBITDA | 2.53x | 2.48x | 3.23x | 4.05x | 4.00x | 4.21x | 4.82x | 5.87x | 4.88x | 3.51x |
| Net Debt / EBITDA | 2.07x | 2.25x | 2.66x | 3.69x | 3.53x | 3.55x | 4.43x | 5.08x | 4.44x | 4.44x |
| Interest Coverage | 5.77x | 7.41x | 6.23x | 4.84x | 7.53x | 6.98x | 4.01x | 1.50x | 3.04x | 3.64x |
| Total Equity | 151.16M▲ 0% | 184.95M▲ 22.4% | 216.01M▲ 16.8% | 188.2M▼ 12.9% | 238.53M▲ 26.7% | 262.44M▲ 10.0% | 282.51M▲ 7.6% | 256.64M▼ 9.2% | 285.68M▲ 11.3% | 332.36M▲ 0% |
| Equity Growth % | 67.06% | 22.36% | 16.79% | -12.87% | 26.74% | 10.03% | 7.65% | -9.16% | 11.32% | 65.02% |
| Book Value per Share | 3.78 | 4.58 | 5.33 | 4.65 | 5.89 | 6.48 | 6.97 | 6.33 | 7.02 | 8.12 |
| Total Shareholders' Equity | 151.16M | 184.95M | 216.01M | 188.2M | 238.53M | 262.44M | 282.51M | 256.64M | 285.68M | 332.36M |
| Common Stock | 4K | 4K | 4K | 4K | 4K | 4K | 4K | 4K | 4K | 4K |
| Retained Earnings | 82.75M | 131.56M | 168.93M | 183.06M | 218.01M | 247.75M | 260.91M | 243.89M | 272.7M | 316.96M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -55.44M | -76.48M | -86.18M | -130.38M | -115.29M | -121.11M | -114.21M | -123.53M | -124.02M | -122.37M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PAHC Cash Flow Statement
Phibro Animal Health Corporation (PAHC) cash flow — operating, investing & free cash flow history
| Line item | Jun'17 | Jun'18 | Jun'19 | Jun'20 | Jun'21 | Jun'22 | Jun'23 | Jun'24 | Jun'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 98.4M | 70.01M | 47.17M | 59.35M | 48.31M | 31.65M | 13.31M | 87.59M | 80.12M | 80.12M |
| Operating CF Margin % | 12.87% | 8.54% | 5.7% | 7.42% | 5.8% | 3.36% | 1.36% | 8.61% | 6.18% | - |
| Operating CF Growth % | 164.39% | -28.85% | -32.62% | 25.82% | -18.61% | -34.48% | -57.95% | 558.11% | -8.53% | 755.93% |
| Net Income | 64.61M | 64.88M | 54.71M | 33.55M | 54.38M | 49.17M | 32.61M | 2.42M | 48.26M | 92.09M |
| Depreciation & Amortization | 26M | 26.94M | 27.56M | 32.34M | 31.89M | 32.7M | 34.01M | 36.18M | 45.6M | 50.75M |
| Stock-Based Compensation | 0 | 334K | 2.26M | 2.26M | 1.13M | 0 | 0 | 475K | 717K | 1.13M |
| Deferred Taxes | -28K | 6.39M | -105K | 8.13M | -2.18M | -806K | -2.84M | -7.84M | -4.88M | 13.75M |
| Other Non-Cash Items | 127.7M | 6.31M | -1.32M | -3.27M | -7.04M | -4.79M | -9.34M | 23.25M | 11.98M | -190K |
| Working Capital Changes | 1.4M | -33.88M | -35.94M | -13.66M | -29.87M | -44.64M | -41.13M | 33.11M | -21.56M | -64.45M |
| Change in Receivables | -2.77M | -11.9M | -23.68M | 28.71M | -18.21M | -23.63M | 5.33M | -8.68M | -55.21M | -15.73M |
| Change in Inventory | 5.43M | -24.29M | -20.98M | -12.93M | -12.5M | -47M | -11.22M | 2.64M | -44.29M | -93.11M |
| Change in Payables | -3.12M | 2.45M | 12.09M | -7.67M | 3.18M | 26.36M | -22.83M | 12M | 45.55M | 27.07M |
| Cash from Investing | -21.9M | -84.61M | -14.13M | -120.39M | -18.58M | -22.58M | -74.02M | -48.19M | -288.69M | -63.48M |
| Capital Expenditures | -20.9M | -18.55M | -29.89M | 0 | -29.32M | -37.04M | -51.79M | -41.24M | -38.29M | -45.79M |
| CapEx % of Revenue | 2.73% | 2.26% | 3.61% | 4.25% | 3.52% | 3.93% | 5.3% | 4.05% | 2.95% | - |
| Acquisitions | 0 | -15M | -9.84M | -54.55M | 29.32M | -13.51M | 0 | -3.28M | -286.53M | 4.3M |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1M | -1.06M | -404K | -34.84M | -30.58M | 620K | 776K | 326K | 1.13M | -2.97M |
| Cash from Financing | -53.74M | -11.78M | -4.11M | 40.94M | -17M | 16.34M | 26.99M | -6.77M | 207.13M | -42.63M |
| Debt Issued (Net) | -39.53M | -1.4M | 13.35M | 60.35M | 5.38M | 40.63M | 42.69M | 12.71M | 235.99M | -259.24M |
| Equity Issued (Net) | 5.54M | 5.7M | 1.13M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | -15.83M | -16.07M | -18.59M | -19.42M | -19.43M | -19.44M | -19.44M | -19.44M | -19.45M | -19.46M |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -3.92M | 0 | 0 | 0 | -2.94M | -4.84M | 3.74M | -31K | -9.4M | 236.06M |
| Net Change in Cash | 22.48M▲ 0% | -26.91M▼ 219.7% | 28.41M▲ 205.5% | -21.23M▼ 174.7% | 13.87M▲ 165.3% | 24.04M▲ 73.3% | -32.97M▼ 237.2% | 29.33M▲ 189.0% | -2.57M▼ 108.8% | -11.59M▲ 0% |
| Free Cash Flow | 77.5M▲ 0% | 51.46M▼ 33.6% | 17.28M▼ 66.4% | 25.3M▲ 46.4% | 18.99M▼ 25.0% | -5.39M▼ 128.4% | -38.48M▼ 613.3% | 46.36M▲ 220.5% | 41.83M▼ 9.8% | 47.29M▲ 0% |
| FCF Margin % | 10.14% | 6.28% | 2.09% | 3.16% | 2.28% | -0.57% | -3.94% | 4.56% | 3.23% | 3.23% |
| FCF Growth % | 8849.19% | -33.6% | -66.42% | 46.45% | -24.97% | -128.42% | -613.33% | 220.46% | -9.76% | 208.53% |
| FCF per Share | 1.94 | 1.27 | 0.43 | 0.62 | 0.47 | -0.13 | -0.95 | 1.14 | 1.03 | 1.03 |
| FCF Conversion (FCF/Net Income) | 1.52x | 1.08x | 0.86x | 1.77x | 0.89x | 0.64x | 0.41x | 36.26x | 1.66x | 0.51x |
| Interest Paid | 14.6M | 11.21M | 12.25M | 11.58M | 10.81M | 11.16M | 14.57M | 17.25M | 32.07M | 0 |
| Taxes Paid | 14.76M | 15.19M | 16.21M | 20.87M | 19.39M | 17.85M | 20.41M | 15.43M | 13.4M | 0 |
PAHC Key Ratios
Phibro Animal Health Corporation (PAHC) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 53.47% | 38.62% | 27.28% | 16.6% | 25.49% | 19.63% | 11.97% | 0.9% | 17.8% | 30.81% |
| Return on Invested Capital (ROIC) | 17.96% | 16.93% | 11.54% | 9.91% | 9.54% | 9.3% | 7.64% | 5.47% | 9.8% | 9.8% |
| Gross Margin | 32.49% | 32.55% | 31.96% | 32.1% | 32.56% | 30.29% | 30.5% | 30.77% | 30.85% | 31.89% |
| Net Margin | 8.45% | 7.91% | 6.61% | 4.19% | 6.53% | 5.22% | 3.33% | 0.24% | 3.72% | 6.29% |
| Debt / Equity | 2.07x | 1.69x | 1.51x | 2.18x | 1.79x | 1.79x | 1.81x | 2.05x | 2.67x | 2.67x |
| Interest Coverage | 5.77x | 7.41x | 6.23x | 4.84x | 7.53x | 6.98x | 4.01x | 1.50x | 3.04x | 3.64x |
| FCF Conversion | 1.52x | 1.08x | 0.86x | 1.77x | 0.89x | 0.64x | 0.41x | 36.26x | 1.66x | 0.51x |
| Revenue Growth | 1.7% | 7.29% | 0.98% | -3.34% | 4.12% | 13.07% | 3.78% | 4.07% | 27.37% | 32.39% |
PAHC SEC Filings & Documents
Phibro Animal Health Corporation (PAHC) SEC filings — annual & quarterly reports (10-K, 10-Q)
PAHC Frequently Asked Questions
Phibro Animal Health Corporation (PAHC) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Phibro Animal Health Corporation (PAHC) reported $1.46B in revenue for fiscal year 2025. This represents a 353% increase from $323.0M in 2000.
Phibro Animal Health Corporation (PAHC) grew revenue by 27.4% over the past year. This is strong growth.
Yes, Phibro Animal Health Corporation (PAHC) is profitable, generating $92.1M in net income for fiscal year 2025 (3.7% net margin).
Dividend & Returns
Yes, Phibro Animal Health Corporation (PAHC) pays a dividend with a yield of 0.81%. This makes it attractive for income-focused investors.
Phibro Animal Health Corporation (PAHC) has a return on equity (ROE) of 17.8%. This is reasonable for most industries.
Phibro Animal Health Corporation (PAHC) generated $47.3M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More PAHC
Phibro Animal Health Corporation (PAHC) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates